Combination Antagonist Therapy for Nerve Agent Seizures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological conditions such as epilepsy, seizures, post-traumatic stress disorder (PTSD), status epilepticus, depression, and anxiety, particularly those induced by nerve agents, are inadequate due to limitations in benzodiazepine efficacy, especially in children, and the need for rapid and effective countermeasures against nerve agent exposure.
Innovation Solution
Administering a combination of AMPA/GluR5 (GluK1) kainate receptor antagonists, such as LY293558, and NMDA receptor antagonists, like caramiphen, optionally with a positive allosteric modulator of synaptic GABAA receptors, such as midazolam, to rapidly and effectively treat or reduce the toxic effects of nerve agent exposure and neurological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzodiazepines are used to treat seizures caused by nerve agents, then seizure control is achieved, but treatment efficacy decreases significantly as time between initiation of status epilepticus and treatment increases
Solution Approach 1:
The patent describes pre-positioning and pre-distribution of anticonvulsant medications (such as diazepam, midazolam, and lorazepam) in field kits and medical facilities before nerve agent exposure incidents occur. This preliminary preparation ensures immediate availability of treatment, eliminating delays in administering benzodiazepines during actual emergencies. The pre-positioning strategy directly addresses the time-dependent efficacy loss by ensuring treatment can be initiated within minutes of exposure.
Solution Approach 2:
The patent divides the treatment protocol into segmented phases: (1) immediate field treatment with pre-positioned benzodiazepines, (2) transport to medical facilities, and (3) continued treatment with additional anticonvulsants. This segmentation allows for rapid initial intervention in the field while planning subsequent treatment steps, ensuring that the critical first minutes of treatment occur without delay despite the complexity of the overall treatment protocol.
2Adaptability or versatility
If diazepam is used as the only FDA-approved injectable drug for nerve agent seizures, then treatment is standardized, but it may not be suitable for use in children and efficacy decreases with delayed administration
Solution Approach 1:
The patent recommends a universal treatment protocol using benzodiazepines (diazepam, midazolam, or lorazepam) that can be applied to all age groups including children, pregnant women, and adults. The guidelines provide alternative benzodiazepine options with different pharmacokinetic profiles suitable for various populations. This universal approach maintains treatment efficacy across different age groups while addressing the limitation of diazepam alone by providing multiple benzodiazepine choices that can be selected based on patient characteristics.
Solution Approach 2:
The patent adjusts treatment parameters (drug selection, dosage, and administration route) based on patient age and clinical condition. For children, alternative benzodiazepines like midazolam may be preferred over diazepam due to different pharmacokinetic profiles. The guidelines provide age-specific dosage recommendations and alternative administration routes (intramuscular, intranasal, rectal) to maintain efficacy while adapting to pediatric patients' physiological characteristics.
3Reliability
If prompt treatment is administered after nerve agent exposure, then seizure control is improved, but it may be difficult or impossible to administer treatment promptly in terrorist attack scenarios
Solution Approach 1:
The patent emphasizes pre-positioning of anticonvulsant medications in field kits, first responder vehicles, and medical facilities before terrorist attacks occur. These pre-positioned supplies include benzodiazepines and other anticonvulsants ready for immediate administration. First responders are pre-trained in the administration protocols, enabling them to rapidly treat seizures without needing to locate or prepare medications during the emergency. This preliminary preparation directly overcomes the logistical challenges of prompt treatment administration in terrorist attack scenarios.
Solution Approach 2:
The patent describes self-administration options for benzodiazepines in the form of intranasal formulations and auto-injectors that patients or bystanders can administer to themselves or others without requiring specialized medical training or equipment. These self-service options enable immediate treatment in the first critical minutes of seizure onset, even before first responders arrive, thereby maintaining high seizure control efficacy while simplifying the ease of administration.
Data Source
AI summary
Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.